Literature DB >> 6883363

Phase II trial of bisantrene for unresectable non-small cell bronchogenic carcinoma: an Illinois Cancer Council study.

W P McGuire, R R Blough, M A Cobleigh, C M Johnson, L J Kukla, T E Lad, V J Lanzotti, P J Stiff, P Zawila.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6883363

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN： 0361-5960


× No keyword cloud information.
  3 in total

1.  A phase II study of bisantrene in malignant lymphomas. A Southwest Oncology Group Study.

Authors:  T P Miller; J D Cowan; B A Neilan; S E Jones
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

2.  Phase II trial of bisantrene in non-small cell lung cancer.

Authors:  T P Miller; F R Ahmann; C Mackel; B R Greenberg; D S Alberts
Journal:  Invest New Drugs       Date:  1985       Impact factor: 3.850

Review 3.  Single-agent chemotherapy for advanced adenocarcinoma of the lung. A review.

Authors:  J B Sørensen; M Clerici; H H Hansen
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.